A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Part of paid clinical trials in Denver, Colorado.

Sponsor
Biohaven Therapeutics Ltd.
Study ID
NCT06874335
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BHV-1530 — DRUG
    BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle

Study Details

This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.

Key Dates

Start date
Mar 20, 2025
Status verified
May 2026
Primary completion
Mar 31, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
95 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: BHV-1530 Monotherapy

Primary Outcome Measure

Dose-escalation and Dose-expansion Cohorts: Number of patients with AEs [ Time Frame: Through study completion, estimated as an average of 48 months ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
Site-107DenverColorado80218-
Site-108Lake MaryFlorida32746-
Site-121MiamiFlorida33136-
Site-110DetroitMichigan48201-
Site-115DurhamNorth Carolina27710-
Site-112Myrtle BeachSouth Carolina29572-
Site-116NashvilleTennessee37203-
Site-103AustinTexas78758-
Site-104HoustonTexas77030-
Site-101IrvingTexas75039-
Site-105San AntonioTexas78229-
Site-106West Valley CityUtah84119-
Site-102FairfaxVirginia22031-

Find similar trials in Denver, CO

By research site
Site-107· Denver, COSite-108· Lake Mary, FLSite-121· Miami, FLSite-110· Detroit, MISite-115· Durham, NCSite-112· Myrtle Beach, SC

Related Studies